PATENT CLAIM ANALYSIS

Application Number: 16222518
Application Type: Utility
Filing Date: 2018-12
Publication Date: 2019-04
Patent Classification: ["514", "183000"]

Abstract:
A method of treating cancer is disclosed comprising administering to a patient in need of such treatment a RXR agonist at a level below the RAR activating threshold and at or above the RXR effective dose.

Claim (Index 3):
The method according to  claim 2 , wherein the RXR effective dose is determined by measuring the reduction of the patient's TSH levels or at least one RAR biomarker expressed by the patient.

Metadata:
- Claim Count in Document: 26.0
- Percentile: 98.0
- Lexical Diversity: 1.19355
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['12079938', '15629591', '15629597', '14994025', '14994031']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7847005388147767
- 35 USC 102 Novelty (BERT): 0.5278430105611025
- Combined Prediction Score: 0.7590147859894093
- Mean Citation Score: 340.401902
- Max Citation Score: 340.70688
- Similarity Product: 326.5201150862504

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test